NO20064388L - Kaseinavledede peptider og terapeutiske anvendelser derav - Google Patents
Kaseinavledede peptider og terapeutiske anvendelser deravInfo
- Publication number
- NO20064388L NO20064388L NO20064388A NO20064388A NO20064388L NO 20064388 L NO20064388 L NO 20064388L NO 20064388 A NO20064388 A NO 20064388A NO 20064388 A NO20064388 A NO 20064388A NO 20064388 L NO20064388 L NO 20064388L
- Authority
- NO
- Norway
- Prior art keywords
- casein
- derived peptides
- therapeutic uses
- derived
- peptides
- Prior art date
Links
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- 239000005018 casein Substances 0.000 title abstract 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 title abstract 2
- 235000021240 caseins Nutrition 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title 1
- 208000023661 Haematological disease Diseases 0.000 abstract 1
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000011132 hemopoiesis Effects 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 231100000252 nontoxic Toxicity 0.000 abstract 1
- 230000003000 nontoxic effect Effects 0.000 abstract 1
- 238000010606 normalization Methods 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 230000000638 stimulation Effects 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4732—Casein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- AIDS & HIV (AREA)
- Transplantation (AREA)
- Tropical Medicine & Parasitology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Biologisk aktive peptider som er avledet fra eller er tilsvarende til sekvensene til (S1- eller (S2, (- eller ?-kaseinfraksjoner av melkekasein. Disse peptidene er i stand til immumnodulering og andre terapeutiske aktiviteter inkludert, men ikke begrenset til, stimulering og fremming av immunrespons, beskyttelse mot viral infeksjon, normalisering av serumkolesterolnivåer og stimulering av hematopoiesis. De kaseinavledede peptidene er ikke-toksiske og kan bli benyttet for å behandle og forhindre immunpatologier, diabetes, hyperkolesterolemia, hematologiske forstyrrelser og viral-relaterte sykdommer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54840104P | 2004-03-01 | 2004-03-01 | |
| PCT/IL2005/000211 WO2005081628A2 (en) | 2004-03-01 | 2005-02-20 | Casein derived peptides and therapeutic uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20064388L true NO20064388L (no) | 2006-11-28 |
Family
ID=34910999
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20064388A NO20064388L (no) | 2004-03-01 | 2006-09-28 | Kaseinavledede peptider og terapeutiske anvendelser derav |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20070203060A1 (no) |
| EP (1) | EP1751179A4 (no) |
| JP (1) | JP2008509073A (no) |
| KR (1) | KR20070007128A (no) |
| CN (1) | CN101124261A (no) |
| AU (1) | AU2005215943A1 (no) |
| BR (1) | BRPI0507822A (no) |
| CA (1) | CA2558155A1 (no) |
| EA (1) | EA200601575A1 (no) |
| MX (1) | MXPA06010014A (no) |
| NO (1) | NO20064388L (no) |
| WO (1) | WO2005081628A2 (no) |
| ZA (1) | ZA200607735B (no) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7750115B2 (en) * | 2004-03-31 | 2010-07-06 | Patent Technology Development, Inc. | Epithelial cell growth promoter |
| DK1831361T3 (da) * | 2004-12-23 | 2012-05-14 | Campina Nederland Holding Bv | Proteinhydrolysat beriget med peptider, som inhiberer DPP-IV, og deres anvendelse |
| EP1851323B1 (en) | 2005-02-24 | 2016-09-28 | DSM IP Assets B.V. | Enzymatic process for producing I-P-P from kappa casein |
| KR20130122979A (ko) | 2005-05-02 | 2013-11-11 | 밀레우티스 엘티디. | 카제인으로부터 유도된 펩티드로 구성된 약학 조성물 및 이를 이용하는 방법 |
| CA2625183C (en) * | 2005-10-04 | 2019-09-03 | Inimex Pharmaceuticals Inc. | Novel peptides for treating and preventing immune-related disorders, including treating and preventing infection by modulating innate immunity |
| EP1951745A2 (en) * | 2005-11-21 | 2008-08-06 | Teagasc Dairy Products Research Centre | Casein-derived antimicrobial peptides and lactobacillus strains that produce them |
| JP2009517464A (ja) * | 2005-11-30 | 2009-04-30 | カンピーナ ネーダーランド ホールディング ビー.ブイ. | グルカゴン様ペプチド1の活性を増強するタンパク質加水分解物の使用 |
| CA2822302A1 (en) | 2006-02-13 | 2007-08-23 | Alethia Biotherapeutics Inc. | Methods of impairing osteoclast differentiation |
| US8168181B2 (en) | 2006-02-13 | 2012-05-01 | Alethia Biotherapeutics, Inc. | Methods of impairing osteoclast differentiation using antibodies that bind siglec-15 |
| JP2007254449A (ja) * | 2006-02-22 | 2007-10-04 | Snow Brand Milk Prod Co Ltd | 脂質改善剤 |
| JP5177778B2 (ja) * | 2006-02-24 | 2013-04-10 | 雪印メグミルク株式会社 | ペプチド |
| GB2436328A (en) * | 2006-03-22 | 2007-09-26 | Regen Therapeutics Plc | Peptide derived from colostrinin |
| CA2649003A1 (en) * | 2006-04-11 | 2007-10-18 | Mileutis Ltd. | Livestock management for improved reproductive efficiency |
| KR20090009862A (ko) * | 2006-04-28 | 2009-01-23 | 유키지루시 뉴교 가부시키가이샤 | 펩티드 |
| EP3231442B1 (en) | 2006-06-23 | 2019-12-25 | ADC Therapeutics SA | Polynucleotides and polypeptide sequences involved in cancer |
| JP5188731B2 (ja) * | 2007-03-02 | 2013-04-24 | 雪印メグミルク株式会社 | ペプチド |
| WO2009138762A2 (en) * | 2008-05-15 | 2009-11-19 | Regen Therapeutics Plc | Therapeutic use of peptides |
| NZ571856A (en) * | 2008-10-09 | 2011-02-25 | Fonterra Corporate Res And Dev Ltd | Use of a phospholipid and ganglioside composition for the treatment or prevention of gout |
| EP3130674B1 (en) | 2008-11-03 | 2020-07-08 | ADC Therapeutics SA | Antibodies that specifically block the biological activity of a tumor antigen |
| DK2370088T3 (en) | 2008-12-27 | 2017-02-20 | Pawan Saharan | Nanopeptides derived from mammalian colostrum for broad-spectrum viral and recurrent infections and methods for isolation thereof |
| MX2011010454A (es) | 2009-04-03 | 2012-01-25 | Nestec Sa | Mejoramiento en la promocion de la sana recuperacion del crecimiento. |
| WO2010144968A1 (en) * | 2009-06-19 | 2010-12-23 | Oral Health Australia Pty Ltd | Casein derived protease inhibitory peptides |
| US8815806B2 (en) | 2009-10-28 | 2014-08-26 | University Of Manitoba | Yellow pea seed protein-derived peptides |
| JP5479884B2 (ja) * | 2009-12-28 | 2014-04-23 | カルピス株式会社 | 脳機能改善用組成物および脳機能を改善する方法 |
| WO2011132191A1 (en) * | 2010-04-21 | 2011-10-27 | Mileutis Ltd. | Casein peptide for use in the treatment of uterine infections |
| PT105073A (pt) * | 2010-04-26 | 2011-10-26 | Consejo Superior Investigacion | Processo de obtenção de extractos peptídicos bioactivos através da hidrólise de proteínas de soro de leite com enzimas de cynara cardunculus, referidos extractos e respectivas utilizações |
| SMT201900505T1 (it) | 2011-03-31 | 2019-11-13 | Adc Therapeutics Sa | Anticorpi contro l'antigene 1 associato ai reni e loro frammenti leganti l'antigene |
| US8865155B2 (en) | 2011-09-29 | 2014-10-21 | Centro De Investigacion En Alimentacion Y Desarrollo, A.C. (Ciad) | Lactococcus lactis strains, and bacterial preparations thereof, for the production of bioactive peptides having anti-hypertensive and cholesterol-lowering effects in mammals; nutritional and therapeutic products produced therefrom |
| CN111298119A (zh) | 2012-01-09 | 2020-06-19 | Adc治疗股份有限公司 | 用于通过使用肾相关抗原1(kaag1)的抑制剂来治疗三阴性乳癌和基底样乳癌的方法 |
| WO2013133032A1 (ja) * | 2012-03-09 | 2013-09-12 | 森永乳業株式会社 | ジペプチジルペプチダーゼ-iv阻害剤 |
| CN104507969A (zh) | 2012-07-19 | 2015-04-08 | 阿莱斯亚生物疗法股份有限公司 | 抗siglec-15抗体 |
| CN102964427B (zh) * | 2012-12-12 | 2014-01-15 | 上海交通大学 | 一种生物活性多肽qepvl及其制备和应用 |
| CN103012552B (zh) * | 2012-12-12 | 2014-03-12 | 上海交通大学 | 一种生物活性多肽qepv及其制备和应用 |
| US9345727B2 (en) * | 2013-03-15 | 2016-05-24 | Mead Johnson Nutrition Company | Nutritional compositions containing a peptide component and uses thereof |
| US9345741B2 (en) | 2013-03-15 | 2016-05-24 | Mead Johnson Nutrition Company | Nutritional composition containing a peptide component with adiponectin simulating properties and uses thereof |
| US9289461B2 (en) * | 2013-03-15 | 2016-03-22 | Mead Johnson Nutrition Company | Reducing the risk of autoimmune disease |
| US10251928B2 (en) * | 2014-11-06 | 2019-04-09 | Mead Johnson Nutrition Company | Nutritional supplements containing a peptide component and uses thereof |
| US9138455B2 (en) | 2013-03-15 | 2015-09-22 | Mead Johnson Nutrition Company | Activating adiponectin by casein hydrolysate |
| US8889633B2 (en) | 2013-03-15 | 2014-11-18 | Mead Johnson Nutrition Company | Nutritional compositions containing a peptide component with anti-inflammatory properties and uses thereof |
| US9352020B2 (en) * | 2013-03-15 | 2016-05-31 | Mead Johnson Nutrition Company | Reducing proinflammatory response |
| ES2899191T3 (es) * | 2014-04-03 | 2022-03-10 | AllerGenis LLC | Péptidos y procedimientos de detección de alergia alimentaria |
| CN104697830B (zh) * | 2015-02-10 | 2018-06-15 | 深圳市新产业生物医学工程股份有限公司 | 用于hiv检测的酸性处理剂、样本预处理方法、试剂盒及检测方法 |
| WO2016208641A1 (ja) * | 2015-06-22 | 2016-12-29 | 株式会社明治 | 血中ヘモグロビン増加用組成物 |
| JP7157043B2 (ja) * | 2017-03-03 | 2022-10-19 | 森永乳業株式会社 | Glp-1分泌促進剤及び組成物 |
| CN107176995B (zh) * | 2017-07-06 | 2019-12-24 | 浙江辉肽生命健康科技有限公司 | 一种生物活性多肽skvlpvpekavpypq及其制备方法和应用 |
| CN107188949B (zh) * | 2017-07-06 | 2019-12-24 | 浙江辉肽生命健康科技有限公司 | 一种生物活性多肽eintvqvtst及其制备方法和应用 |
| EP3682892A4 (en) * | 2017-09-15 | 2021-10-27 | Kine Sciences Co., Ltd. | USE OF PEPTIDES AS A THERAPEUTIC AGENT AGAINST AUTOIMMUNE AND BONE DISEASES |
| CN107903314A (zh) * | 2017-11-14 | 2018-04-13 | 上海交通大学 | 一种生物活性多肽eviesppeintv及其制备方法和应用 |
| TWI655203B (zh) * | 2017-11-16 | 2019-04-01 | 國立中興大學 | 新穎胜肽、含有該胜肽之組合物及其用途 |
| CN107814835B (zh) * | 2017-12-01 | 2020-04-28 | 熊猫乳品集团股份有限公司 | 一种生物活性多肽avpitptlnreq及其制备方法和应用 |
| CN107814839A (zh) * | 2017-12-07 | 2018-03-20 | 浙江辉肽生命健康科技有限公司 | 一种生物活性多肽pigsensekttmpl及其制备方法和应用 |
| CN107880102A (zh) * | 2017-12-07 | 2018-04-06 | 浙江辉肽生命健康科技有限公司 | 一种生物活性多肽peviesppein及其制备方法和应用 |
| CN107759682B (zh) * | 2017-12-07 | 2021-03-02 | 浙江辉肽生命健康科技有限公司 | 一种生物活性多肽pigsensgkttmpl及其制备方法和应用 |
| CN107827971B (zh) * | 2017-12-07 | 2020-04-14 | 浙江辉肽生命健康科技有限公司 | 一种生物活性多肽qsltltdve及其制备方法和应用 |
| CN107880106B (zh) * | 2017-12-11 | 2020-06-16 | 浙江辉肽生命健康科技有限公司 | 一种生物活性多肽vpitptlnre及其制备方法和应用 |
| CN107880105B (zh) * | 2017-12-11 | 2020-06-16 | 浙江辉肽生命健康科技有限公司 | 一种生物活性多肽vpitptlnr及其制备方法和应用 |
| CN107827972A (zh) * | 2017-12-11 | 2018-03-23 | 浙江辉肽生命健康科技有限公司 | 一种生物活性多肽speviesppein及其制备方法和应用 |
| CN108017703B (zh) * | 2017-12-11 | 2020-07-17 | 浙江辉肽生命健康科技有限公司 | 一种生物活性多肽vpitptln及其制备方法和应用 |
| CN107880104A (zh) * | 2017-12-11 | 2018-04-06 | 浙江辉肽生命健康科技有限公司 | 一种生物活性多肽sppeintvqvt及其制备方法和应用 |
| CN108034002A (zh) * | 2017-12-12 | 2018-05-15 | 浙江辉肽生命健康科技有限公司 | 一种生物活性多肽peviesppeintv及其制备方法和应用 |
| CN107814840B (zh) * | 2017-12-12 | 2020-04-10 | 浙江辉肽生命健康科技有限公司 | 一种生物活性多肽pkypvepf及其制备方法和应用 |
| CN108017709B (zh) * | 2017-12-12 | 2020-04-10 | 浙江辉肽生命健康科技有限公司 | 一种生物活性多肽kepmigvnqela及其制备方法和应用 |
| CN108017708A (zh) * | 2017-12-12 | 2018-05-11 | 浙江辉肽生命健康科技有限公司 | 一种生物活性多肽npigsensekttmpl及其制备方法和应用 |
| CN107880108A (zh) * | 2017-12-12 | 2018-04-06 | 浙江辉肽生命健康科技有限公司 | 一种生物活性多肽sfsdipnpigse及其制备方法和应用 |
| KR102073824B1 (ko) * | 2018-04-11 | 2020-02-05 | 강원대학교산학협력단 | 간 보호용 건강기능식품 및 이의 제조 방법 |
| WO2023272386A1 (en) * | 2021-06-29 | 2023-01-05 | Gill Thomas A | Peptides for regulating glucose |
| CN113952446B (zh) * | 2021-09-03 | 2023-12-05 | 河南省医药科学研究院 | 生物活性肽在抑制骨髓毒性中的应用 |
| CN116333151B (zh) * | 2022-08-12 | 2023-08-25 | 广西壮族自治区水牛研究所 | 一种用于检测水牛奶中掺假普通牛乳的单克隆抗体及其制备方法和用途 |
| NL2033588B1 (en) * | 2022-11-22 | 2024-05-30 | Univ Ningbo | Duck liver protein-derived anti-inflammatory and antimicrobial functional peptide and preparation method and application thereof |
| CN119320440A (zh) * | 2023-07-06 | 2025-01-17 | 中国科学院大连化学物理研究所 | 一种抗菌肽及其应用 |
| CN117567586A (zh) * | 2023-10-25 | 2024-02-20 | 广州菲勒生物科技有限公司 | 一种富含唾液酸化肽的水解酪蛋白的制备方法及其在调节肠道菌群中的应用 |
| CN118452475A (zh) * | 2024-04-10 | 2024-08-09 | 江南大学 | 一种促钙吸收后生元的制备方法及其应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5968901A (en) * | 1989-10-30 | 1999-10-19 | Andersson; Bengt | Antibacterial composition |
| US5707968A (en) * | 1994-05-26 | 1998-01-13 | Abbott Laboratories | Inhibition of attachment of H.influenzae to human cells |
| IL134830A0 (en) * | 2000-03-01 | 2001-05-20 | Chay 13 Medical Res Group N V | Peptides and immunostimulatory and anti-bacterial pharmaceutical compositions containing them |
| TWI268138B (en) * | 2000-05-11 | 2006-12-11 | Kanebo Seiyaku Ltd | Composition containing peptide and electrolyte excretion enhancing substance, and food containing the same |
| MXPA04001890A (es) * | 2001-08-30 | 2004-06-18 | Chay 13 Medical Res Group N V | Peptidos derivados de caseina y sus usos en terapia. |
-
2005
- 2005-02-20 BR BRPI0507822-9A patent/BRPI0507822A/pt not_active IP Right Cessation
- 2005-02-20 AU AU2005215943A patent/AU2005215943A1/en not_active Abandoned
- 2005-02-20 WO PCT/IL2005/000211 patent/WO2005081628A2/en not_active Ceased
- 2005-02-20 EA EA200601575A patent/EA200601575A1/ru unknown
- 2005-02-20 MX MXPA06010014A patent/MXPA06010014A/es not_active Application Discontinuation
- 2005-02-20 JP JP2007501441A patent/JP2008509073A/ja active Pending
- 2005-02-20 CN CNA2005800140129A patent/CN101124261A/zh active Pending
- 2005-02-20 US US10/591,405 patent/US20070203060A1/en not_active Abandoned
- 2005-02-20 EP EP05709111A patent/EP1751179A4/en not_active Withdrawn
- 2005-02-20 CA CA002558155A patent/CA2558155A1/en not_active Abandoned
- 2005-02-20 KR KR1020067020558A patent/KR20070007128A/ko not_active Withdrawn
-
2006
- 2006-09-15 ZA ZA200607735A patent/ZA200607735B/en unknown
- 2006-09-28 NO NO20064388A patent/NO20064388L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA06010014A (es) | 2007-03-07 |
| CN101124261A (zh) | 2008-02-13 |
| ZA200607735B (en) | 2008-05-28 |
| JP2008509073A (ja) | 2008-03-27 |
| WO2005081628A3 (en) | 2007-10-18 |
| AU2005215943A1 (en) | 2005-09-09 |
| CA2558155A1 (en) | 2005-09-09 |
| EP1751179A2 (en) | 2007-02-14 |
| BRPI0507822A (pt) | 2007-07-10 |
| US20070203060A1 (en) | 2007-08-30 |
| EA200601575A1 (ru) | 2007-06-29 |
| WO2005081628A2 (en) | 2005-09-09 |
| KR20070007128A (ko) | 2007-01-12 |
| EP1751179A4 (en) | 2009-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20064388L (no) | Kaseinavledede peptider og terapeutiske anvendelser derav | |
| DK1261360T3 (da) | Casein-afledte peptider og anvendelser deraf i behandling | |
| DE502005010615D1 (de) | Mittel zur behandlung von entzündlichen erkrankungen | |
| NO20092522L (no) | Sammensetninger og fremgangsmater for a behandle kreft med cupredoxiner og CPG rikt DNA | |
| EA200801071A1 (ru) | Способы и композиции для применения в целях лечения пациентов с положительным по аутоантителам заболеванием | |
| EA200971053A1 (ru) | Способы лечения кожных язв | |
| ATE476983T1 (de) | Immunostimulierende polynukleotide sequenzen zur verwendung bei der verhinderung und behandlung von viralen erkrankungen der atemwege | |
| WO2006066008A3 (en) | Device and methods for identifying and treating aspirin non-responsive patients | |
| NO20060483L (no) | VEGF-feller og terapeutiske anvendelser derav | |
| EA201000644A1 (ru) | Антитела для лечения и профилактики болезни альцгеймера и их применение | |
| NO20092639L (no) | 4-fenyl-6-(2,2,2-trifluor-1-fenyletoksy)pynmidinbaserte forbindelser og anvendelser derav | |
| NO20070372L (no) | Amidoforbindelser og anvendelse derav som farmasoytiske preparater | |
| NO20080084L (no) | Molekyler som er i stand til a hemme bindingen mellom NGF og TrkA-reseptoren som analgetika med forlenget effekt | |
| EP2338996A3 (en) | Methods and compositions for reducing viral genome amounts in a target cell | |
| ATE503769T1 (de) | Antikörper gegen das humane cytomegalie-virus (hcmv) | |
| MX2011013296A (es) | Metodos de tratamiento o prevención de enfermedad asociada a influenza con soluciones acuosas con potencial de oxidación-reduccion. | |
| CA2821268C (en) | Human monoclonal antibody with specificity for dengue virus serotype 1 e protein and uses thereof | |
| NO20076405L (no) | Anvendelse av 24-nor-UDCA | |
| Chen et al. | Roles of ubiquitin-specific proteases in inflammatory diseases | |
| ATE382383T1 (de) | Apherese-vorrichtung | |
| WO2004066942A3 (en) | Purification and uses of dendritic cells and monocytes | |
| NO20071706L (no) | Koadministrering av Tigecycline og Digoxin. | |
| WO2005077462A3 (en) | Cd70 inhibition for the treatment and prevention of inflammatory bowel disease | |
| KR20040078639A (ko) | 카세인 유도 펩타이드 및 이들의 치료 용도 | |
| NO20055474L (no) | Mediatorer av revers kolesteroltransport for behandling av hyperkolesterolemi |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |